Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 7, 2016

Lucideon and Skyepharma to develop iCRT-deter abuse deterrent

Lucideon has signed an exclusive feasibility, development and licence agreement with a subsidiary of oral and inhalation drug development company Skyepharma.

By Lopamudra Roy

Lucideon has signed an exclusive feasibility, development and licence agreement with a subsidiary of oral and inhalation drug development company Skyepharma.

Under the agreement, Skyepharma’s oral business will have access to Lucideon’s proprietary iCRT-deter abuse deterrent controlled release technology.

iCRT-deter is a drug delivery technology part of Lucideon’s inorganic controlled release platforms.

The technology has been designed in a way that makes drugs difficult to tamper with by several methods including chewing, heating and crushing, while maintaining the necessary controlled release properties.

" … This project is an excellent example of how we work with industry to maximise the properties of materials to meet their technical and commercial needs."

Lucideon healthcare business manager Gemma Budd said: "With features such as an extremely high melting point, and a highly porous particulate structure that maintains the controlled release and abuse deterrent features even when crushed, we believe that iCRT-deter will play a pivotal role in deterring abuse of multiple prescription drugs in the future, a technological advancement that benefits not only patients and providers, but society as a whole.

"The iCRT technology platform has other pharmaceutical applications outside of abuse-deterrence, but this project is an excellent example of how we work with industry to maximise the properties of materials to meet their technical and commercial needs."

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Lucideon will collaborate with Skyepharma’s oral business in order to evaluate the feasibility of using the technology with an aim to create an abuse deterrent formulation of a major opioid for the US market.

After the success of the feasibility stage, Skyepharma will produce the product as a generic for the US market.

iCRT-deter has been developed as a result of the rising prescription drug abuse problem in many areas across the globe.

In the US, where drug abuse problem is recognised as an epidemic, the Food and Drug Administration (FDA) has proposed an action plan that includes the development of abuse-deterrent formulations of opioid products.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU